论文部分内容阅读
据世界在研新药动态(Pharmaprojects)记载,目前,在新药研发的适应症中,有世界第一杀手之称的各类癌症占据了所有适应症总和的五分之一。鉴于新药发展的趋势,能上市的新化学实体(NCEs)越来越少。然而,pharmaprojects一份列出了所有当前正在进行的药品研究与开发项目数据库分析报告显示,尽管普遍的下滑走势还要持续两年多时间,此后新产品的数量将重新上升。一、1567造就大金矿分析报告认为,癌症领域作为新药研发的最活跃地带,很可能会爆出未来竞争最多的适应症。
According to the world’s research reports on Pharmaprojects, at present, among the indications developed for new drugs, all kinds of cancers, which are the No. 1 killers in the world, occupy one fifth of the sum of all indications. In view of the trend of new drug development, fewer and fewer new chemical entities (NCEs) can be listed. However, a pharmaprojects database listing all currently underway drug research and development projects shows that although the general downturn will continue for more than two years, the number of new products will rise again. A large gold mine in 1567 Analysis report that the field of cancer as the most active drug development, is likely to burst out the most competitive indications.